|»5 Minute Wrap Up by Equitymaster|
On This Day - 12 SEPTEMBER 2018
Is It the Right Time to Buy Pharma Stocks Now?
It's been fifteen months since we launched Smart Money Secrets.
My team and I have recommended sixteen stocks so far (15 buy recommendations and 1 buy at lower level recommendation).
That's not something that happened by chance. I have consciously stayed away from this sector.
It is not that I haven't met the management of any pharma company. In fact, Sarvajeet and I met a couple of them earlier.
But I didn't recommend them because there was no clarity.
If you go back in time a bit, between 2005-2015, the US generics market was the most important driver of growth and profitability for Indian pharma companies.
Back then, it was all about figuring out when a drug was to come 'off patent' and then quickly making a cheaper generic version.
That era is over. Now, the dynamics of the generics business is changing.
There is price erosion due to consolidation at the distributor's level in the US. Earlier, there were eight distributors. Now, this came down to just three. With this, the distributors now have a better bargaining power.
Also, improved pace of approvals by the USFDA has resulted in rising competition as well as pressure on pricing.
Apart from this, the absence of niche product launches, in the US, was another important reason for their poor performance in the last couple of years.
| --- Advertisement ---
One Would Be A LOT Richer Today If He Had Done THIS Earlier…
Majority of investors out there think about investing in companies like Titan, MRF and Pidilite only after they've turned big. But for a second, imagine a person had invested in them when they were small and relatively unknown.
Yes! Doing that back then would have made him a LOT richer today. But it's not too late yet.
In our latest special report we unveil 3 small companies that have taken the market by storm and are well on their way to becoming blue-chips in their segments. So don't let this opportunity go.
Click here to find out how you can get our latest report containing full details on these 3 stocks and more for virtually FREE!
Through this initiative, the pharma industry is trying to gradually move up in the value chain.
However, this will entail significant front-ended investments. The corresponding revenue will accrue over a period of time.
Think of it as short-term pain for long-term gain.
Similarly, pharma companies are learning to cope with FDA inspections better. They are improving incrementally. Earlier, they didn't know which areas they needed to improve as per strict USFDA standards. Now they know.
Not to mention, the recent tariff cuts by China on Indian medicines that will open up another major overseas market for the Indian pharma companies.
Last but not least, the pharma companies earn a majority of their revenue in foreign currency. With the rupee falling to 72, investors are looking for businesses that earn revenue in US dollars.
So, is the pharma sector poised for a comeback? Is the worst over?
I believe so.
FY18 was a tough year for pharma companies. But FY19 is shaping up well. And I expect FY20 to be even better.
Although there will some challenges ahead, the recovery is on in full swing and I am excited!
In fact, as I wrote to you last week, Sarvajeet and I will be travelling to meet a pharma company.
| --- Advertisement ---
Proven Way to Get Cherry Picked Investment Ideas from 8 of Our Best Research Services…
Equitymaster Insider, one of our most popular services gives its subscribers around 1 cherry-picked investment idea from 8 of our premium services, every week …
That makes it around 48 investment ideas every year!
And for a limited time, you can join in at a special discount…
Click here for immediate access…
2018 has been an eventful year, to say the least. The Sensex touched all-time high of 38,990 last month.
The rupee touched an all-time low of 72.74 yesterday. The crude is going up and gained around 13% in 2018.
The midcap and smallcap indices are feeling the heat. They are down by about 9% and 13% respectively. Whereas, the Sensex is the outperformer with an increase of 12%.
I thought it would be an interesting exercise to see how sectorial indices are performing in 2018.
Here's the result.
Over the last three months, the BSE Healthcare index rose by 24%.
With the rupee breaching the 72 mark, IT and pharma are outperforming all other indices.
In the near term, the rupee being under pressure could benefit export-oriented businesses.
My last month's Smart Money Secrets recommendation will benefit from the rupee depreciation.
The company derives around 65% of the revenue from exports. The icing on the cake is the company's focused entry into the B2C segment, which provides it a long runway for future growth.
I believe, the potential upside in this stock is 79%.
If you're a Smart Money Secrets subscriber, read the detailed report here.
Kunal Thanvi (Research Analyst)
Editor, Smart Money Secrets
PS: Kunal Thanvi, editor of Smart Money Secrets, is the Sherlock Holmes of investing. He is on a mission to reveal the top picks of India's best investors to you. For clean, high quality stock recommendations that won't put your wealth at risk, subscribe to Kunal's Smart Money Secrets.
PPS: Ajit Dayal, our founder, will be talking at the Indian Merchant Chamber, Churchgate on the Lehman Crisis on the 15th of September 2018. Those of you who are interested in attending this event can sign up here.